Listing 1 - 10 of 102 << page
of 11
>>
Sort by

Book
Slavica poematia Latine reddita : eine fruhe sudslavische Volksliedsammlung
Authors: ---
ISBN: 3412094978 Year: 1997 Publisher: Köln : Böhlau Verlag,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Materialy k biografii.
Authors: --- ---
ISBN: 5867932958 Year: 2005 Publisher: Moskva Novoe literaturnoe obozrenie

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
The rise and fall of the Soviet Politburo
Authors: --- ---
Year: 1992 Publisher: London UCL Press

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
Maladies des organes génito-urinaires et goutte
Author:
Year: 1868 Publisher: Paris : Chamerot et Lauwereyns,

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
Third-Generation EGFR Inhibitors
Authors: --- ---
ISBN: 0081026625 0081026617 9780081026625 9780081026618 Year: 2019 Publisher: Amsterdam

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
Fast Facts : EGFR Exon 20 Insertion Mutations in NSCLC
Authors: --- --- ---
ISBN: 3318071366 3318070203 Year: 2022 Publisher: Abingdon, Oxford : S. Karger AG,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Lung cancer is still a major cause of death globally, but the development of personalized, precision medicine has had a marked effect on treatment management and improved clinical outcomes, particularly for those with advanced stage non-small-cell lung cancer (NSCLC). EGFR mutations are the third most common mutation found in patients with advanced stage NSCLC. First-line treatment with a traditional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is indicated for most patients, but not for patients with EGFR exon 20 insertion mutations (ex20ins). Instead, recent approvals of an EGFR ex20ins-specific TKI (mobocertinib) and a bispecific antibody (amivantamab) targeting both EGFR and mesenchymalepithelial transition factor (MET) offer the potential for improved outcomes in this patient population. Furthermore, new approaches to treatment continue to be developed and trials for new agents with greater activity against ex20ins mutations are ongoing.


Book
Small animal medicine and metabolic disorders
Author:
ISBN: 9781138392434 9781138035720 Year: 2019 Publisher: Boca Raton : CRC Press

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
Campbell-Walsh-Wein handbook of urology
Authors: --- --- ---
ISBN: 9780323827478 Year: 2022 Publisher: Philadelphia, PA : Elsevier,

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
Les thérapies ciblées
Authors: ---
ISBN: 9782287360077 2287360077 9782287360084 9786611960261 1281960268 2287360085 Year: 2008 Publisher: Paris : Springer-Verlag,

Loading...
Export citation

Choose an application

Bookmark

Abstract

En 2008, les progrès des connaissances en matière de la carcinogenèse ont permis d'identifier des cibles moléculaires clés dans la genèse de nombreuses tumeurs solides. Bien que non exhaustives encore, ces informations permettent l'utilisation de composés dirigés contre les cibles moléculaires, spécifiquement activées dans les cancers donnant ainsi naissance au concept de thérapie ciblée. Le trastuzumab, dirigé contre HER2 dont le gène est amplifié dans 20 % des adénocarcinomes du sein, et l'imatinib, inhibiteur de kinase dirigé contre la protéine de fusion bcr/abl, issu de la t(9,22) des leuc

Saami religion : based on papers read at the symposium on Saami religion held at Aabo on the 16th-18th of August 1984
Author:
ISBN: 9122008632 Year: 1987 Volume: 12 Publisher: Aabo Stockholm The Donner Institute for research in religious and cultural history Almqvist & Wiksell

Listing 1 - 10 of 102 << page
of 11
>>
Sort by